It has been indicated that isoforms of mir-29 can inversely regulate B7-H3 expression in various cancers, e.g., neuroblastoma [28], cutaneous melanoma [41], breast cancer [35], diffuse brain glioma [29], colorectal cancer [44], and medulloblastoma [37]. This evidence concerns the gene CD276 and cutaneous melanoma.